WHO: Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. https://www.who.int/publications/i/item/9789240027077.
Unemo M, et al. Gonorrhoea. Nat Rev Dis Prim. 2019;5:79.
WHO: Treatment of Neisseria gonorrhoeae. https://iris.who.int/bitstream/handle/10665/246114/9789241549691-eng.pdf.
Unemo M, et al. WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017–18: a retrospective observational study. Lancet Microbe. 2021;2:e627–636.
Xiu L, Zhang L, Peng J. Surge in ceftriaxone-resistant Neisseria gonorrhoeae FC428-like strains, Asia-Pacific region, 2015−2022. Emerg Infect Dis. 2024;30:1683–6.
Fifer H, Doumith M, Rubinstein L, Mitchell L, Wallis M. Ceftriaxone-resistant Neisseria gonorrhoeae detected in England, 2015–24: an observational analysis. J Antimicrob Chemother. 2024;79:3332–9.
Melendez JH, et al. Local emergence and global evolution of Neisseria gonorrhoeae with high-level resistance to azithromycin. Antimicrob Agents Chemother. 2024;68:e0092724.
Eyre DW, et al. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Eur Surveill. 2018;23:1800323.
Caméléna F, et al. Emergence of extensively drug-resistant Neisseria gonorrhoeae, France, 2023. Emerg Infect Dis. 2024;30:1903–6.
Wagenlehner F, et al. Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials. Lancet. 2024;403:741–55.
Ross JDC, et al. Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study. Lancet. 2025;405:1608–20.
Wang XC, et al. Frenolicins C-G, Pyranonaphthoquinones from sp RM-4-15. J Nat Prod. 2013;76:1441–7.
Tsukamoto M, et al. New cytotoxic agents, BE-52440A and B, produced by a streptomycete. J Antibiotics. 2000;53:687–93.
Tatsuta K, Suzuki Y, Toriumi T, Furuya Y, Hosokawa S. The first total synthesis and structural determination of (+)-BE-52440A. Tetrahedron Lett. 2007;48:8018–21.
Derewacz DK, et al. Structure and Stereochemical Determination of Hypogeamicins from a Cave-Derived Actinomycete. J Nat Prod. 2014;77:1759–63.
Ding X, et al. Crepidamycins A-E, pyranonaphthoquinones from endophytic Streptomyces sp. MG-F-1 of Dendrobium crepidatum by the co-culture strategy. Phytochem. 2025;233:114404.
Nakayama S, et al. New ceftriaxone- and multidrug-resistant Neisseria gonorrhoeae strain with a novel mosaic penA gene isolated in Japan. Antimicrob Agents Chemother. 2016;60:4339–41.
Yahara K, et al. Genomic surveillance of Neisseria gonorrhoeae to investigate the distribution and evolution of antimicrobial-resistance determinants and lineages. Microb Genomics. 2018;4:e000205.
Zarantonelli L, Borthagaray G, Lee EH, Shafer WM. Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations. Antimicrob Agents Chemother. 1999;43:2468–72.
Veal WL, Nicholas RA, Shafer WM. Overexpression of the MtrC- MtrD-MtrE efflux pump due to an mtrR mutation is required for chromosomally mediated penicillin resistance in Neisseria gonorrhoeae. J Bacteriol. 2002;184:5619–24.
Naysmith BJ, Hume PA, Sperry J, Brimble MA. Pyranonaphthoquinones – isolation, biology and synthesis: an update. Nat Prod Rep. 2017;34:25–61.
Ye Q, et al. Frenolicin B targets peroxiredoxin 1 and glutaredoxin 3 to trigger ROS/4E-BPl-mediated antitumor effects. Cell Chem Biol. 2019;26:366–77.
